Damora Therapeutics Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Election of two Class III directors — Michael Landsittel and Cameron Turtle, D.Phil — to serve three‑year terms expiring at the 2029 annual meeting.

2. 2

   Approval, on an advisory basis, of the compensation paid to our named executive officers

   ManagementBoard: FOR

   Non‑binding advisory “say‑on‑pay” vote to approve the compensation paid to the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This proposal asks shareholders to cast a non‑binding advisory vote to approve the company’s named executive officer compensation as disclosed in the proxy. Management is pursuing this approval as a routine governance practice (a “say‑on‑pay” vote) required by Section 14A and to obtain shareholder feedback on its compensation policies, which the Compensation Committee views as aligned with company strategy and retention objectives. The compensation program described emphasizes a mix of base salary, cash bonuses (including retention bonuses tied to transactions or milestones), and equity incentives to align executives’ interests with long‑term shareholder value. The context includes recent retention payments and separation arrangements disclosed for certain executives, as well as accelerated equity vesting in certain severance events, which could influence shareholder sentiment about pay-for-performance alignment. The board recommends a FOR vote, stating that the Compensation Committee believes the policies and practices effectively implement the company’s compensation philosophy and achieve program goals; it also notes that the advisory vote is not binding but will be considered in future decisions. Key governance considerations for an analyst include the prominence of retention and separation payments (including recent acceleration of equity upon a CEO separation), the company’s status as a smaller reporting company (which affects disclosure), and the degree to which equity awards drive realized pay and link to TSR. Given these factors, an analyst should weigh whether disclosed pay practices appropriately tie payouts to long‑term performance, the transparency of severance/retention arrangements, and the company’s rationale for its compensation design when evaluating the merits of the Board’s recommendation.

3. 3

   Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation

   ManagementBoard: FOR

   Non‑binding advisory choice among one year, two years, or three years for the frequency of future say‑on‑pay votes; the Board recommends one year.

   More detail

   This proposal asks shareholders to indicate, on a non‑binding basis, whether future advisory votes on executive compensation should be held every one, two or three years. Management supports an annual frequency and frames the vote as a mechanism to obtain more frequent and direct shareholder input on compensation practices. The Board’s recommendation for annual voting is grounded in considerations of transparency and accountability: more frequent votes allow shareholders to respond quickly to material changes in pay practices or corporate performance and give the Compensation Committee more immediate feedback. From an analyst perspective, the issues to consider include tradeoffs between responsiveness and administrative burden—annual votes increase engagement opportunities but can encourage short‑term focus—versus multi‑year votes that provide a longer runway for multi‑year incentive plans. Company‑specific context includes recent management and organizational changes (CEO transition and retention payments) and evolving compensation arrangements, which could justify more frequent shareholder feedback in the near term. The vote is non‑binding; the Board will consider the plurality outcome and may adopt the option receiving the most votes. Analysts should assess whether annual voting will meaningfully improve governance oversight of pay or simply increase proxy activity without changing substantive compensation design.

4. 4

   Ratification of the Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Upcoming shareholder meetings at Damora Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Damora Therapeutics Inc 2026 annual meeting?

Damora Therapeutics Inc (DMRA) holds its 2026 annual shareholder meeting on Wednesday, June 17, 2026.

What is the record date for the Damora Therapeutics Inc 2026 meeting?

The record date for the Damora Therapeutics Inc 2026 meeting is Wednesday, April 22, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Damora Therapeutics Inc's 2026 meeting?

The board is presenting 2 director nominees at the Damora Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Damora Therapeutics Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Damora Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.